SCND · XBRL financial data

Scientific Industries financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SCND's year ends in late December)

In thousands of dollars	FY 2020Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	9,775	11,401	—	11,112	10,713	5,054
Cost of revenue	4,800	5,664	—	6,010	5,979	3,751
Gross profit	4,975	5,737	—	5,102	4,734	1,303
Research and development	1,624	2,873	—	3,566	2,906	2,488
General and administrative	4,029	5,817	—	5,418	4,823	3,269
Total operating expenses	9,684	13,001	—	14,362	11,372	9,193
Other operating income (expense)	572	185	—	—	12	711
Operating income (loss)	(4,709)	(7,264)	—	(9,260)	(6,638)	(7,890)
Interest income	82	—	—	—	—	—
Other income (expense)	—	185	—	63	193	—
Income tax expense (benefit)	(1,153)	(1,349)	—	0	0	5
Net income (loss)	(3,673)	(5,644)	—	(9,087)	(6,445)	(1,220)
Earnings per share, basic USD per share	(1.00)	—	—	—	—	—
Earnings per share, diluted USD per share	(1.00)	—	—	(1.27)	(0.61)	(0.11)
Weighted average shares, diluted thousands of shares	3,190	6,637	—	10,145	10,504	11,345

Fiscal years (SCND's year ends in late December)

In thousands of dollars	FY 2020Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	9,675	2,971	1,927	796	588	955
Short-term investments	—	—	—	—	—	5,705
Accounts receivable	1,295	1,501	1,313	1,157	1,203	866
Inventory	2,977	4,696	4,860	4,884	4,086	1,401
Prepaid and other current assets	351	548	457	414	353	1,115
Total current assets	18,431	16,269	12,990	12,341	8,288	10,389
Property and equipment, net	413	1,006	1,163	1,082	885	691
Right-of-use asset	665	1,476	1,374	1,274	948	924
Goodwill	4,395	4,395	115	115	115	115
Total assets	29,006	29,032	18,069	16,731	11,561	12,608
Accounts payable	454	1,106	887	712	586	449
Accrued liabilities	634	796	822	778	790	417
Total current liabilities	2,287	2,230	2,120	1,837	1,747	1,349
Lease liability, non-current	461	1,240	1,156	1,008	694	595
Total liabilities	2,782	3,470	3,277	2,845	2,441	1,945
Accumulated deficit	(651)	(6,296)	(18,399)	(27,485)	(33,931)	(35,151)
Total stockholders' equity	26,225	25,562	14,793	13,885	9,119	10,663
Total liabilities and equity	29,006	29,032	18,069	16,731	11,561	12,608
Common shares outstanding (cover page) thousands of shares	6,458	7,004	7,004	10,504	10,504	11,929

Fiscal years (SCND's year ends in late December)

In thousands of dollars	FY 2020Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,673)	(5,644)	—	(9,087)	(6,445)	(1,220)
Stock-based compensation	2,108	2,351	—	2,240	1,165	521
Depreciation and amortization	252	688	—	—	—	—
Net cash from operating activities	(3,302)	(5,512)	—	(6,155)	(3,684)	—
Purchases of property and equipment	199	758	—	132	99	63
Net cash from investing activities	(10,884)	(3,749)	—	(735)	2,866	3,831
Proceeds from issuing common stock	—	3,000	—	6,283	717	2,050
Net cash from financing activities	16,310	2,628	—	5,751	646	1,952
Net change in cash	2,116	(6,704)	—	(1,131)	(208)	328

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Scientific Industries	617	1,470	(904)*	11.9M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Bioforce Nanosciences Holdings	0.3	not reported	(27)*	33.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
ASTROTECH	8,387	not reported	(2,288)*	2.0M	5.0 quarters	Q4 FY26 10-KJun 30, 2026
Electro Sensors	10,756	not reported	68	3.5M	—	Q1 FY26 10-QMar 31, 2026
Radnostix	1,196	2,672	(614)*	529.2M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Lifeloc Technologies	908	2,445	(133)*	2.8M	6.8 quarters	Q2 FY26 10-QJun 30, 2026
Syntec Optics Holdings	14,047	8,274	(299)*	40.3M	47.0 quarters	Q2 FY26 10-QJun 30, 2026
US Nuclear	67	352	(127)	62.8M	0.5 quarters	Q1 FY26 10-QMar 31, 2026
Bionano Genomics	3,730	8,171	(4,670)*	11.8M	2.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.